Hope for a rare disease: eculizumab in neuromyelitis optica (Q46178439)

20 December 2017

title

Hope for a rare disease: eculizumab in neuromyelitis optica (English)

1 reference

20 December 2017

0 references

Friedemann Paul

1

0 references

publication date

26 April 2013

1 reference

20 December 2017

published in

Lancet Neurology

1 reference

20 December 2017

volume

12

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

529-531

1 reference

20 December 2017

The spectrum of neuromyelitis optica

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Association of neuromyelitis optica with severe and intractable pain.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Failure of natalizumab to prevent relapses in neuromyelitis optica.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Treatment of Neuromyelitis Optica: Review and Recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970089-9

7 January 2021

10.1016/S1474-4422(13)70089-9

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

23623398

1 reference

20 December 2017